{"id":271200,"date":"2023-07-18T06:54:02","date_gmt":"2023-07-18T06:54:02","guid":{"rendered":"https:\/\/www.thetruthseeker.co.uk\/?p=271200"},"modified":"2023-07-20T06:15:45","modified_gmt":"2023-07-20T06:15:45","slug":"a-new-low-for-vax-depravity-in-russia","status":"publish","type":"post","link":"https:\/\/www.thetruthseeker.co.uk\/?p=271200","title":{"rendered":"A new low for vax depravity in Russia"},"content":{"rendered":"

The genetic precursor to Sputnik V, GamEvac, was never approved for use outside of Russia, even though it was supposed to serve as the platform for Gamaleya\u2019s COVID injection.<\/p>\n

Edward Slavsquat \u2013 edwardslavsquat.substack.com July 17, 2023<\/strong><\/h1>\n

The Gamaleya Center is developing mRNA “canned food” for future injections<\/h3>\n

For any semi-sane government, the Pandemic should have been a \u201cteachable moment\u201d, and arguably the most important lesson gleaned from this globally coordinated war on public health would be: \u201cWe should probably stop with those genetic injections, shouldn\u2019t we?\u201d<\/p>\n

Unfortunately there is growing evidence that the Russian government concluded the exact opposite.<\/p>\n

Russia\u2019s vax evangelists want a \u201cmRNA vaccine platform\u201d so they can \u201cimmunize a patient often, a lot, and for a long time.\u201d We\u2019ll return to this comment in a moment, but first some background.<\/p>\n

The Gamaleya Center\u2014the alleged mastermind behind Sputnik V\u2014announced last week that it would begin<\/a> Phase I trials for FiloPan, a new Ebola \u201cvaccine\u201d.<\/p>\n

\"\"<\/a><\/div>\n

\u201cThe FiloPan vaccine uses a defective adenovirus. It is safe for humans, as it is not able to multiply in the body. It inserts a gene that codes for the Ebola protein, or Marburg. Here, the same principle is applied that was used for vaccination against COVID-19,\u201d Anatoly Altshtein, professor at the Gamaleya Center, told Izvestia.<\/p>\n

Now I will explain why this is deeply problematic.<\/p>\n

First, the image that Izvestia used does not show FiloPan. It is a photograph of GamEvac and GamEvac-Combi, the Ebola vaccines that were developed almost a decade ago, and purportedly served as the \u201csafe and effective genetic platform\u201d that allowed for the turbo-charged creation of Sputnik V.<\/p>\n

Sputnik V\u2019s \u201cproven formula based on an approved Ebola shot\u201d has been a central talking point employed by both Gamaleya and the drug\u2019s main financer, the Russian Direct Investment Fund (RDIF).<\/p>\n

RDIF CEO and WEF Young Global Leader Kirill Dmitriev told<\/a> CNN in August 2020: \u201cWe chose the safest approach, it has been extensively tested not only now, but also in the Ebola vaccine that has been approved earlier.\u201d<\/p>\n

A month later, Kirill wrote<\/a> in an op-ed for RT.com: \u201cRussia has benefitted from modifying for COVID-19 an existing two-vector vaccine platform developed in 2015 for Ebola fever, which went through all phases of clinical trials and was used to help defeat the Ebola epidemic in Africa in 2017.\u201d<\/p>\n

Both of these statements are hilarious lies, which this blog already meticulously debunked<\/a>. (Guinea was declared Ebola-free in June 2016<\/a> and remained that way for nearly five years. Contrary to Dmitriev\u2019s insane outbursts, there was no Ebola epidemic in need of \u201cdefeating\u201d when Gamaleya\u2019s scientists arrived in Guinea in 2017 to begin small-scale tests of their experimental shot, which was tested on about 2,000 Guineans, and only received emergency use authorization in Russia, where there is obviously lots and lots of Ebola.)<\/p>\n

TASS, citing Gamaleya director Alexander Gintsburg, reported<\/a> in December 2020 that \u201cthe Sputnik V coronavirus vaccine, based on the same platform used to develop the Ebola drug, is likely to be able to protect the body for two years.\u201d (Gintsburg quickly changed his tune, explaining<\/a> that Russians would need \u201cinfinite\u201d biannual booster shots to protect themselves from the Virus.)<\/p>\n

Of course, we have to ask: If Russia\u2019s original Ebola injection was so amazing, and if it really was a \u201cproven\u201d platform that gave birth to Sputnik V, why would you need to create a new Ebola vaccine? WHY?<\/em><\/p>\n

Furthermore, why did Mr. Altshtein fail to mention that Sputnik V was allegedly based on a pre-existing Ebola vaccine, and not the other way around?<\/p>\n

Even more curious is that Gamaleya actually received approval<\/a> to begin tests on its \u201cnew\u201d Ebola vaccine in October 2022<\/em>, but is only now injecting FiloPan into 64 adult volunteers.<\/p>\n

Russia\u2019s Clinical Trial Authorization Registry (RCT) shows<\/a> that Phase I trials for FiloPan started on October 10, 2022, and are slated to end on December 30, 2023. And now they\u2019re beginning the trial in \u2026 July 2023? A bit odd.<\/p>\n

I suspect we\u2019ll be seeing more of this oddness in the very near future.<\/p>\n

In a May interview<\/a> with TASS (that I missed, but discovered while researching this blog post), the deputy director of Gamaleya, Denis Logunov, claimed that FiloPan was developed back in 2017, during Phase I trials for GamEvac-Combi, and was apparently just sitting on a shelf somewhere. Sure, why not?<\/p>\n

\"\"<\/a><\/div>\n

The whole interview is a real eye-opener, but here are my favorite parts:<\/p>\n

TASS: Are African countries interested in these vaccine preparations now?<\/p>\n

Logunov: Now we are on the way to creating the so-called canned food\u2014the basis for future vaccines<\/strong>. There are especially dangerous pathogens that can pose a threat both in Africa and in the Russian Federation. We must have a set of vaccine preparations, not necessarily brought to mass production, but passed the first and second phases of clinical trials, which can be quickly translated into medical practice if necessary.<\/strong><\/p>\n

[\u2026]<\/p>\n

TASS: Do you think a vaccine [for HIV] can appear, given the variability of the virus?<\/p>\n

Logunov: Of course, we are thinking about it. It is clear that in the last 40 years people have been struggling with the idea of \u200b\u200b\u200b\u200bcreating a vaccine, but so far it has not been very successful. In principle, there is a certain phenomenology that allows you to rely on it in attempts to create new versions of vaccine preparations. Therefore, we need to continue to create vaccines. This is where an mRNA vaccine platform can help\u2014you can immunize a patient often, a lot, and for a long time, even with weak T-cell immunogens. This is where this technology can shine.\u00a0<\/strong><\/p>\n

To sum up: Russia\u2019s most trusted public health experts want genetic \u201ccanned food\u201d that can be spoon-fed to the proles when \u201cdangerous pathogens\u201d appear. And also, an mRNA platform can \u201chelp\u201d protect public health, because one of the benefits of mRNA injections is that you can \u201cimmunize a patient, often, a lot, and for a long time.\u201d This is where mRNA goo \u201cshines\u201d.<\/p>\n

All of this is old news, of course, since Gamaleya announced<\/a> almost a year ago that it was developing its own mRNA COVID shot (why even bother when you have millions of unused doses of a safe and effective AstraZeneca clone<\/a> rotting in warehouses?).<\/p>\n

\"\"<\/a><\/p>\n

Sorry for sounding like a worrywart, but it seems like the plan is to inject everyone, everywhere, forever. Trust the Science.<\/strong><\/h3>\n